

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	1/1/1952
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Quetiapine, Serum or Plasma

Quetiapine, Serum/Plasma	113 ng/mL INTERPRETIVE INFORMATION: Que	(Ref Interval: 100-1000) etiapine, Serum or Plasma
	Therapeutic range: 100-1000 n Toxic: Greater than 1000 ng/n	
	of schizophrenia and bipolar quetiapine are influenced by inhibit or induce CYP3A4 met	ic drug indicated for the treatment disorder. The pharmacokinetics of drug-drug interactions that may abolism. Adverse effects may include ziness, fatigue, constipation,
	determined by ARUP Laborator approved by the US Food and I	its performance characteristics ies. It has not been cleared or Drug Administration. This test was d laboratory and is intended for

VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
Quetiapine, Serum/Plasma	23-240-152508	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: